Algemeen Ziekenhuis Delta

Research site

Belgium Sint-Rembertlaan 21, 8820 Torhout, Belgium

2 trials recruiting
Hormone-dependent prostate cancer · Squamous cell carcinoma of lung · Non-small cell lung cancer
Adults and children

About Specializations

Algemeen Ziekenhuis Delta in Torhout, Belgium specialises in clinical trials of conditions such as Hormone-dependent prostate cancer, Squamous cell carcinoma of lung, Non-small cell lung cancer, Non-small cell lung cancer stage IV, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Sint-Rembertlaan 218820 TorhoutBelgium

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 5

More sites in Torhout Belgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

3 clinical trials

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Contact Research Centre

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:OSE Immunotherapeutics

Contact Research Centre

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Belgium

Participants:0–17 years · 18–64 years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites